Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
$20.55-3.88%
报价 2026-11-13
市值
$714.9M
EV
$650.2M
PE (TTM)
113.9x
预期 PE (FY2026)
432.2x
52 周区间距高点 -5.6%
$8.19$21.77
筛选结果
pipeline · 2026-11-13Keep✓ 高增长✗ Cheap✗ GARP
Growth Pool: next 1Y revenue growth > 30%
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.8x | 0.16 → 0.13(0.8x) | 153.1 |
| FY+32028-12 | 2.2x | 0.16 → 0.30(1.9x) | 69.0 |
毛利率 129% · TTM 收入 $75M · 基数 EPS 0.16(调整后)
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DCTHDelcath Systems, Inc. | $714.9M | -3.9% | +32.9% | 128.7% | 113.9x | 77.0x | 35.0x | 高增长 |
| AGLAgilon Health, Inc. | $1.94B | +4.9% | +0.7% | 6.4% | – | – | – | |
| TCMDTactile Systems Technology, Inc. | $600.6M | -0.0% | +13.4% | 75.2% | 31.1x | 13.8x | 20.7x | GARP |
| SENSSenseonics Holdings, Inc. | $579.6M | +5.4% | +92.0% | 58.7% | – | – | – | 高增长 |
| MASS908 Devices Inc. | $405M | -0.5% | +26.7% | 49.8% | – | – | 911.9x | |
| CERSCerus Corporation | $400.9M | +2.3% | +10.4% | 52.1% | – | 226.7x | – | GARP |
| BWAYBrainsWay Ltd. | $396.5M | -1.4% | – | 75.4% | 62.4x | 74.0x | – | |
| NPCENeuroPace, Inc. | $260.5M | -37.1% | +5.5% | 77.2% | – | – | – | |
| RXSTRxSight, Inc. | $223.1M | -1.1% | -1.7% | 76.6% | – | – | 12.0x | |
| 同行中位数 | – | – | +10.4% | 66.9% | 46.7x | 74.0x | 20.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。